Loading...
Pharmacy Channel Adoption And Bihormonal Pipeline Will Drive Long Term Diabetes Care Impact
AN
AnalystConsensusTarget
Not Invested
Based on Analyst Price Targets
Published
14 Dec 25
Views
9
14 Dec
US$13.88
AnalystConsensusTarget's Fair Value
US$31.30
55.7% undervalued intrinsic discount1Y
-22.4%7D
-4.5%1Y
-22.4%7D
-4.5%You can edit this narrative until Dec 15 10:05 PM. Then, changes will post as Updates.
Author's Valuation
US$31.355.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value